PADI4 and chronic obstructive pulmonary disease: These later studies indicate promise for the future development of PAD-based therapeutics for RA and for preserving lung function in patients with COPD, with the caveat of targeting extracellular PAD activity while preserving PAD antimicrobial activity within neutrophil phagosomes.